Help | Scores |Exit
Fragmin | Magnex | Solu Medrol
Captopril Drug Name:  
A|B|C|D|E|F|G|H|I|K|L|M|N|O|P|Q|R|S|T|V|Z
Quick Dosage
Class
Indications
Dosages
Route
Interactions
Contraindications
Precautions
Adverse Reactions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions:

Allopurinol

  • Adverse Effect: hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions)  
  • Clinical Management: If these drugs are used concurrently, monitor for hypersensitivity reactions.

    Amiloride

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Antacids Comb.

  • Adverse Effect: Decreased captopril effectiveness  
  • Clinical Management: Concurrent administration of antacids and captopril is not recommended. If concurrent use cannot be avoided, captopril should be taken at least two hours before antacids are administered.

    Aspirin

  • Adverse Effect: decreased captopril effectiveness  
  • Clinical Management: Although studies have suggested an interaction between Captopril and aspirin, the clinician should weigh the benefits against the risks of combining these two agents.

    Bumetanide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Captopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Celecoxib

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Chlorthalidone

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of Captopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Clopamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of Clopamide in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Diclofenac Preps.

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Erythropoietin

  • Adverse Effect: higher maintenance doses of erythropoietin to maintain the target hematocrit  
  • Clinical Management: Monitor patients receiving Captopril for erythropoietin efficacy. When given concomitantly, doses of erythropoietin may be higher than expected.

    Flurbiprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Frusemide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Captopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Ibuprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Indapamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Captopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Indomethacin

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketoprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketorolac

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Lithium

  • Adverse Effect: Lithium toxicity (weakness, tremor, excessive thirst, confusion) and/or nephrotoxicity  
  • Clinical Management: The combination of lithium and Captopril should be avoided if possible, though the choice of an alternative antihypertensive agent that does not interact with lithium is limited. If lithium and Captopril are used concurrently, serum lithium levels should be closely monitored and the patient followed for any symptoms of lithium toxicity.

    Mefenamic Acid

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Meloxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nabumetone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Naproxen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nimesulide

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Oxyphenbutazone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Paracetamol

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenacetin

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenylbutazone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Piroxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Spironolactone

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Tenoxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Xipamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the Captopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Antacids: Decreased effects of cap-topril. Separate administration times.

    Aspirin, indomethacin, other NSAIDs: May de-crease captopril*s antihypertensive effect. Use together cautiously.

    Digoxin: May increase serum digoxin levels. Mon-itor digoxin levels.

    Diuretics, other antihypertensives: Enhanced antihypertensive effects. Monitor blood pressure closely.

    Lithium: Increased lithium levels, which may lead to toxicity. Use together with caution; monitor lithium drug levels.

    Phenothiazines: May lead to increased pharmacologic effects. Monitor patient closely.

    Potassium-sparing diuretics, potassium supple-ments: Increased serum potassium levels. Mon-itor serum potassium level closely.
  • Calcium Salts
    Captopril
    Carbamazepine
    CastorOil
    Cefaclor
    Cefadroxil
    CefazolinSodium
    Cefdinir
    CefepimeHydrochloride
    Cefixime
    CefotaximeSodium
    CeftriaxoneSodium
    CefuroximeAxetil
    Cephalexin Hydrochloride Monohydrate
    CetirizineHydrochloride
    Chloral Hydrate
    Chloramphenicol
    Chlordiazepoxide
    Chloroquine Hydrochloride
    Chlorpheniramine Maleate
    Chlorpromazine Hydrochloride
    Chlorthalidone
    Cholestyramine
    Cimetidine
    Ciprofloxacin
    Ciprofloxacin Hydrochloride
    Cisplatin
    Clarithromycin
    ChemastineFumarate
    Clindamycin Hydrochloride
    Clonazepam
    Clotrimazole
    CloxacillinSodium
    CodeinePhosphate
    CortisoneAcetate
    Co-trimoxazole
    CromolynSodium
    Cyanocobalamin
    Cycloserine
    Cyclosporine
    Chlormezanone
    Chlorpropamide
    Clostebol
    Clotrimazole - Topical
    Clotrimazole - VU
    Clozapine
    Coal Tar
    Colchicine
    Colistin Sulphate
    Colloidal Bismuth
    Conj Estrogen
    Corticotrophin
    Cotrimoxazole
    Crotamiton
    Cyclandelate
    Cyclopentolate
    Cyclophosphamide
    Cyproheptadine
    Cytarabine
    Calcipotriol
    Calcitonin
    Calcium Dobesilate
    Candesartan
    Capreomycin
    Carbenicillin
    Carbidopa
    Carbimazole
    Carboplatin
    Carboprost
    Cardioplegia
    Carisoprodol
    Carvedilol
    Catalin
    Cefoperazone
    Cefpirome
    Cefpodoxime
    Ceftazidime
    Ceftibuten
    Ceftizoxime
    Cefuroxime
    Celecoxib
    Celiprolol
    Centchroman
    Cephaloridine
    Cetrimide
    Chenodeoxycholic acid
    Chlorambucil
    Chlorhexidine Gluconate
    Chloroxylenol
    Chlorzoxazone
    Cholera Vaccine
    Ciclopiroxolamine
    Ciclopiroxolamine - VU
    Cinnarizine
    Cisapride
    Citalopram
    Clemastine
    Clidinium Br
    Clidinium Br - Antispas
    Clobazam
    Clobetasol
    Clofazimine
    Clomiphene
    Clomipramine
    Clonidine
    Clopamide
    Clopidogrel
     
    Disclaimer